Biomedical System Dynamics to Improve Anemia Control With Darbepoetin Alfa in Long-Term Hemodialysis Patients
- 1 January 2014
- journal article
- research article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 89 (1) , 87-94
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Development of an erythropoietin prescription simulator to improve abilities for the prescription of erythropoietin stimulating agents: Is it feasible?BMC Nephrology, 2011
- Exposure‐Response Modeling of Darbepoetin Alfa in Anemic Patients With Chronic Kidney Disease Not Receiving DialysisThe Journal of Clinical Pharmacology, 2010
- Randomized Trial of Model Predictive Control for Improved Anemia ManagementClinical Journal of the American Society of Nephrology, 2010
- Association of Hemoglobin Variability and Mortality among Contemporary Incident Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2008
- Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)Kidney International, 2008
- Hemoglobin Level VariabilityClinical Journal of the American Society of Nephrology, 2008
- Hemoglobin Variability and Mortality in ESRDJournal of the American Society of Nephrology, 2007
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietinKidney International, 2005
- Reversal of Left Ventricular Hypertrophy Following Recombinant Human Erythropoietin Treatment of Anaemic Dialysed Uraemic PatientsNephrology Dialysis Transplantation, 1991